Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology ( IF 12.9 ) Pub Date : 2022-08-22 , DOI: 10.1002/hep.32746
Sandra Torres _{1,

2,

3} , Cristina Ortiz ₁ , Nadine Bachtler ₁ , Wenyi Gu _{1,

4} , Leon D Grünewald ₅ , Nico Kraus ₁ , Robert Schierwagen _{1,

4} , Christoph Hieber ₁ , Caroline Meier ₁ , Olaf Tyc ₁ , Maximilian Joseph Brol _{1,

4} , Frank Erhard Uschner _{1,

4} , Bart Nijmeijer ₆ , Christoph Welsch ₁ , Marie-Luise Berres ₇ , Carmen Garcia-Ruiz _{2,

3,

8} , Jose Carlos Fernandez-Checa _{2,

3,

8} , Christian Trautwein ₇ , Thomas J Vogl ₅ , Stefan Zeuzem ₁ , Jonel Trebicka _{1,

4,

9} , Sabine Klein _{1,

4}

Affiliation

Department of Internal Medicine I , Goethe University Clinic Frankfurt , Frankfurt , Germany.
Department of Cell Death and Proliferation , Instituto Investigaciones Biomédicas de Barcelona (IIBB), Spanish National Research Council (CSIC) , Barcelona , Spain.
Liver Unit-IDIBAPS and Centro de Investigación Biomédica en Red (CIBERehd) , Barcelona , Spain.
Department of Internal Medicine B , University of Münster , Münster , Germany.
Department of Diagnostic and Interventional Radiology , Universit+y Hospital Frankfurt , Frankfurt am Main , Germany.
Research and Development Department , Linxis BV , Amsterdam , The Netherlands.
Department of Internal Medicine III , Aachen University Hospital , Aachen , Germany.
Department of Medicine , University of Southern California, Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
European Foundation for the Study of Chronic Liver Failure - EF Clif , Barcelona , Spain.

Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo.

中文翻译：

pacritinib 抑制 Janus 激酶 2 作为肝纤维化的潜在治疗靶点

Janus 激酶 2 (JAK2) 信号在人类和实验性肝纤维化伴门静脉高压症中增加。 JAK2 抑制剂，例如 pacritinib，已经处于其他适应症的高级临床开发阶段，并且可能对肝纤维化有效。在这里，我们研究了 JAK2 抑制剂 pacritinib 对体外激活的肝星状细胞 (HSC) 和两种体内肝纤维化动物模型的抗纤维化作用。

更新日期：2022-08-22

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11